Formycon AG (LON:0W4N)
United Kingdom · Delayed Price · Currency is GBP · Price in EUR | Market Cap | 219.21M -26.9% |
| Revenue (ttm) | 52.73M +18.3% |
| Net Income | -21.64M |
| EPS | -1.19 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 58.76 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 399 |
| Open | 14.50 |
| Previous Close | 14.58 |
| Day's Range | 14.30 - 14.50 |
| 52-Week Range | 13.66 - 26.85 |
| Beta | 0.70 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 12, 2026 |
About Formycon AG
Formycon AG, a biotechnology company, develops biosimilar drugs in Germany and Switzerland. It provides ranibizumab and aflibercept used in the treatment of neovascular age-related macular degeneration, diabetic macular edema, choroidal neovascularization, proliferative diabetic retinopathy, and macular edema under the Ranivisio, Ongavia, Cimerli, Ranopto, Uptera, and Ravegza brand names, as well as AHZANTIVE, Baiama, and Fovlya brand names. The company’s pipeline includes ustekinumab used in the treatment of Crohn’s disease, ulcerative colitis... [Read more]
Financial Performance
In 2025, Formycon AG's revenue was 44.48 million, a decrease of -36.17% compared to the previous year's 69.67 million. Losses were -64.70 million, -48.52% less than in 2024.
Financial numbers in EUR Financial StatementsNews
Formycon Revises EBITDA Guidance After FYB201/FYB202 Non-Cash Impairments
Formycon faces a tougher outlook as biosimilar impairments hit earnings, prompting a cut to its 2026 adjusted EBITDA forecast while revenue guidance remains unchanged.
Formycon Holds 2026 Outlook, Revises Adj. EBITDA, Reassesses FYB201/202
Pricing pressure is weighing on Formycon’s biosimilars, prompting lower adjusted EBITDA guidance and €121 million in non-cash impairments, while its next-generation pipeline remains unaffected.
EQS-News: Formycon maintains 2026 guidance for revenue, EBITDA and working capital, revises adjusted EBITDA and reassesses FYB201 and FYB202
EQS-News: Formycon AG / Key word(s): Change in Forecast Formycon maintains 2026 guidance for revenue, EBITDA and working capital, revises adjusted EBITDA and reassesses FYB201 and FYB202 05.11.2026 / ...
EQS-Adhoc: Formycon AG recognizes non-cash impairments on FYB201 and FYB202 and revises its guidance for adjusted EBITDA
EQS-Ad-hoc: Formycon AG / Key word(s): Forecast / Other Formycon AG recognizes non-cash impairments on FYB201 and FYB202 and revises its guidance for adjusted EBITDA 05-Nov-2026 / 14:44 CET/CEST Discl...
EQS-News: Formycon invites to conference call on 2026 nine-month results and announces participation in international investor conferences
EQS-News: Formycon AG / Key word(s): Miscellaneous Formycon invites to conference call on 2026 nine-month results and announces participation in international investor conferences 05.11.2026 / 06:30 C...
Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy
Original-Research: Formycon AG - from First Berlin Equity Research GmbH 03.11.2026 / 14:47 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group. The issuer is solely ...
EQS-AFR: Formycon AG: Preliminary announcement of the publication of quarterly reports and quarterly/interim statements
EQS Preliminary announcement financial reports: Formycon AG / Preliminary announcement on the disclosure of financial statements Formycon AG: Preliminary announcement of the publication of quarterly r...
EQS-News: Formycon and Biocelys Combine Complementary Development and Manufacturing Expertise in New Biosimilar Project FYB286
EQS-News: Formycon AG / Key word(s): Alliance Formycon and Biocelys Combine Complementary Development and Manufacturing Expertise in New Biosimilar Project FYB286 21.10.2026 / 06:30 CET/CEST The issue...
EQS-RPT: Formycon AG: Release according to Article 111c of the AktG [the German Stock Corporation Act] with the objective of Europe-wide distribution
EQS Related Party Transactions announcement: Formycon AG / Release of an announcement according to Article 111c of the AktG [the German Stock Corporation Act] Formycon AG: Release according to Article...
USFDA accepts biosimilar application of Zydus and German firm for Keytruda
NEW DELHI: Zydus Lifesciences and Formycon AG, an independent developer of biosimilars, jointly announced that the US Food and Drug Administration (USFDA)
FDA Accepts BLA For Formycon And Zydus' Keytruda Biosimilar FYB206 ;Shares Rise
(RTTNews) - Formycon AG (FYB.DE), an independent developer of biosimilars, and Zydus Lifesciences Ltd., a life sciences company, jointly announced that the U.S. Food and Drug Administration (FDA) has ...
EQS-News: Formycon and Zydus: FYB206 Becomes First Publicly Announced Keytruda Biosimilar Accepted for Review by FDA
EQS-News: Formycon AG / Key word(s): Regulatory Admission Formycon and Zydus: FYB206 Becomes First Publicly Announced Keytruda Biosimilar Accepted for Review by FDA 13.10.2026 / 06:00 CET/CEST The iss...
EQS-News: Formycon Optimizes Biosimilar Development with AI-Powered Technologies: Digital Solutions Enhance Development Efficiency as Part of the FYB4GROWTH Strategy
EQS-News: Formycon AG / Key word(s): Alliance Formycon Optimizes Biosimilar Development with AI-Powered Technologies: Digital Solutions Enhance Development Efficiency as Part of the FYB4GROWTH Strateg...
EQS-News: Formycon sets Benchmark in Biosimilar Development: Scientific Foundation of the innovative Development Program for FYB206 published in the Journal BioDrugs
EQS-News: Formycon AG / Key word(s): Scientific publication Formycon sets Benchmark in Biosimilar Development: Scientific Foundation of the innovative Development Program for FYB206 published in the J...
Formycon AG Earnings Call Transcript: Q2 2026
H1 2026 saw revenues nearly triple year-over-year, driven by strong commercialization of FYB202 and FYB206, with adjusted EBITDA improving significantly. The outlook remains positive with further revenue growth expected from FYB202 royalties and milestone payments for FYB206, while the company maintains a strong equity ratio and continues to invest in its pipeline.
Formycon AG Quarterly report: Q2 2026
Formycon AG has published its Q2 2026 quarterly earnings report on August 12, 2026.
Formycon AG Earnings release: Q2 2026
Formycon AG released its Q2 2026 earnings on August 12, 2026, summarizing the period's financial results.
Formycon AG Slides: Q2 2026
Formycon AG has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 12, 2026.
EQS-News: Formycon reports key operational achievements in the first half of 2026 and significantly improves financial results year-on-year
EQS-News: Formycon AG / Key word(s): Half Year Results/Half Year Report Formycon reports key operational achievements in the first half of 2026 and significantly improves financial results year-on-yea...
EQS-News: Formycon invites to conference call on 2026 half-year results and announces participation in international investor conferences
EQS-News: Formycon AG / Key word(s): Miscellaneous Formycon invites to conference call on 2026 half-year results and announces participation in international investor conferences 05.08.2026 / 06:30 CE...
EQS-AFR: Formycon AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]
EQS Preliminary announcement financial reports: Formycon AG / Preliminary announcement on the disclosure of financial statements Formycon AG: Preliminary announcement of the publication of financial r...
Formycon AG Slides: Company presentation
Formycon AG has posted slides in relation to its latest quarterly earnings report, which was published on August 1, 2026.
EQS-News: Formycon AG and OneSource Specialty Pharma announce strategic Manufacturing Partnership for Biosimilars
EQS-News: Formycon AG / Key word(s): Miscellaneous Formycon AG and OneSource Specialty Pharma announce strategic Manufacturing Partnership for Biosimilars 14.07.2026 / 06:30 CET/CEST The issuer is sol...
EQS-News: Formycon AG Reports Results of Annual General Meeting 2026
EQS-News: Formycon AG / Key word(s): AGM/EGM Formycon AG Reports Results of Annual General Meeting 2026 10.06.2026 / 16:22 CET/CEST The issuer is solely responsible for the content of this announcemen...
Formycon AG Transcript: Jefferies Global Healthcare Conference 2026
The company is accelerating its biosimilar portfolio, with three products launched and several more in advanced stages. Regulatory changes and strategic regional partnerships are driving growth, with revenue and profitability targets set for 2026.